Mycoplasma infection suppresses p53, activates NF-κB and cooperates with oncogenic Ras in rodent fibroblast transformation

Oncogene

Volumn 27, Issue 33, 2008, Pages 4521-4531

  Logunov, D Y ^a   Scheblyakov, D V ^a   Zubkova, O V ^a   Shmarov, M M ^a   Rakovskaya, I V ^a   Gurova, K V ^b   Tararova, N D ^b   Burdelya, L G ^b,c   Naroditsky, B S ^a   Ginzburg, A L ^a   Gudkov, A V ^b,c  

^a GAMALEYA RESEARCH INSTITUTE OF EPIDEMIOLOGY AND MICROBIOLOGY   (Russian Federation)

^b CLEVELAND BIOLABS INC   (United States)

^c ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Oncogene; p21; Senescence; Transactivation; Tumor suppressor

Indexed keywords

BETA GALACTOSIDASE; CYCLIN DEPENDENT KINASE INHIBITOR 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN P53; SHORT HAIRPIN RNA;

ANIMAL CELL; ANIMAL CELL CULTURE; APOPTOSIS; ARTICLE; BACTERIAL GENE; BACTERIAL INFECTION; CANCER SUSCEPTIBILITY; CARCINOGENICITY; CELL CYCLE ARREST; CELL GROWTH; CELL LINE; CONTROLLED STUDY; CULTURE MEDIUM; DNA RESPONSIVE ELEMENT; DOWN REGULATION; EMBRYO; FIBROBLAST; GENE EXPRESSION REGULATION; GENE REPRESSION; GENOTOXICITY; HUMAN; HUMAN CELL; MALIGNANT TRANSFORMATION; MOUSE; MUTAGENICITY; MYCOPLASMA; MYCOPLASMA ARGININE; NONHUMAN; ONCOGENE H RAS; PRIORITY JOURNAL; PROMOTER REGION; RAT; TUMOR CELL; TUMOR SUPPRESSOR GENE;

ANIMALS; APOPTOSIS; CELL LINE; CELL TRANSFORMATION, NEOPLASTIC; CHROMOSOMAL INSTABILITY; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DNA DAMAGE; EMBRYO, MAMMALIAN; FIBROBLASTS; HUMANS; MICE; MYCOPLASMA; MYCOPLASMA INFECTIONS; NF-KAPPA B; PROTO-ONCOGENE PROTEINS P21(RAS); RATS; RESPONSE ELEMENTS; TUMOR SUPPRESSOR PROTEIN P53;

BACTERIA (MICROORGANISMS); MYCOPLASMA; MYCOPLASMA ARGININI; PROKARYOTA; RATTUS; RODENTIA;

EID: 48649098798     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2008.103     Document Type: Article

References (37)

1. Baek KH, Shin HJ, Yoo JK, Cho JH, Choi YH, Sung YC et al. (2003). p53 deficiency and defective mitotic checkpoint in proliferating T lymphocytes increase chromosomal instability through aberrant exit from mitotic arrest. J Leukoc Biol 73: 850-861.
2. Boiko AD, Porteous S, Razorenova OV, Krivokrysenko VI, Williams BR, Gudkov AV et al. (2006). A systematic search for downstream mediators of tumor suppressor function of p53 reveals a major role of BTG2 in suppression of Ras-induced transformation. Genes Dev 20: 236-252.
3. Bubici C, Papa S, Pham CG, Zazzeroni F, Franzoso G. (2006). The NF-kappaB-mediated control of ROS and JNK signaling. Histol Histopathol 21: 69-80.
4. Burgert HG, Ruzsics Z, Obermeier S, Hilgendorf A, Windheim M, Elsing A. (2002). Subversion of host defense mechanisms by adenoviruses. Curr Top Microbiol Immunol 269: 273-318.
5. Chu HW, Jeyaseelan S, Rino JG, Voelker DR, Wexler RB, Campbell K et al. (2005). TLR2 signaling is critical for Mycoplasma pneumoniae-induced airway mucin expression. J Immunol 9: 5713-5719.
6. Cimolai N. (2001). Do mycoplasmas cause human cancer? Can J Microbiol 47: 691-697.
7. Correa P, Houghton J. (2007). Carcinogenesis of Helicobacter pylori. Gastroenterology 133: 659-672.
8. De Marzo AM, Platz EA, Sutcliffe S, Xu J, Grönberg H, Drake CG et al. (2007). Inflammation in prostate carcinogenesis. Nat Rev Cancer 7: 56-69.
9. Donehower LA, Godley LA, Aldaz CM, Pyle R, Shi YP, Pinkel D et al. (1996). The role of p53 loss in genomic instability and tumor progression in a murine mammary cancer model. Prog Clin Biol Res 395: 1-11.
10. Efeyan A, Serrano M. (2007). p53: guardian of the genome and policeman of the oncogenes. Cell Cycle 6: 1006-1010.
11. Feng SH, Tsai S, Rodriguez J, Lo SC. (1999). Mycoplasmal infections prevent apoptosis and induce malignant transformation of interleukin-3-dependent 32D hematopoietic cells. Mol Cell Biol 12: 7995-8002.
12. Ferbeyre G, de Stanchina E, Lin AW, Querido E, McCurrach ME, Hannon GJ et al. (2002). Oncogenic ras and p53 cooperate to induce cellular senescence. Mol Cell Biol 22: 3497-3508.
13. Gartel AL, Tyner AL. (1999). Transcriptional regulation of the p21((WAF1/CIP1)) gene. Exp Cell Res 246: 280-289.
14. Gurova KV, Hill JE, Guo C, Prokvolit A, Burdelya LG, Samoylova E et al. (2005). Small molecules that reactivate p53 in renal cell carcinoma reveal a NF-kappaB-dependent mechanism of p53 suppression in tumors. Proc Natl Acad Sci USA 48: 17448-17453.
15. Gurova KV, Hill JE, Razorenova OV, Chumakov PM, Gudkov AV. (2004). p53 pathway in renal cell carcinoma is repressed by a dominant mechanism. Cancer Res 64: 1951-1958.
16. Jiang S, Zhang S, Langenfeld J, Lo SC, Rogers MB. (2007). Mycoplasma infection transforms normal lung cells and induces bone morphogenetic protein 2 expression by post-transcriptional mechanisms. J Cell Biochem e-pub ahead of print 4 Dec 2007.
17. Karin M. (2006). Nuclear factor-kappaB in cancer development and progression. Nature 441: 431-436.
18. Karin M, Lawrence T, Nizet V. (2006). Innate immunity gone awry: linking microbial infections to chronic inflammation and cancer. Cell 124: 823-835.
19. Komarova EA, Chernov MV, Franks R, Wang K, Armin G, Zelnick CR et al. (1997). Transgenic mice with p53-responsive lacZ: p53 activity varies dramatically during normal development and determines radiation and drug sensitivity in vivo. EMBO J 16: 1391-1400.
20. Lee CH, Jeon YT, Kim SH, Song YS. (2007). NF-kappaB as a potential molecular target for cancer therapy. Biofactors 29: 19-35.
21. Lisowska K, Witkowski JM. (2003). Viral strategies in modulation of NF-kappaB activity. Arch Immunol Ther Exp (Warsz) 51: 367-375.
22. Lu T, Burdelya LG, Swiatkowski SM, Boiko AD, Howe PH, Stark GR et al. (2004a). Secreted transforming growth factor beta2 activates NF-kappaB, blocks apoptosis, and is essential for the survival of some tumor cells. Proc Natl Acad Sci USA 18: 7112-7117.
23. Lu T, Sathe SS, Swiatkowski SM, Hampole CV, Stark GR. (2004b). Secretion of cytokines and growth factors as a general cause of constitutive NFkappaB activation in cancer. Oncogene 12: 2138-2145.
24. Mantovani F, Banks L. (2001). The human papillomavirus E6 protein and its contribution to malignant progression. Oncogene 20: 7874-7887.
25. McCormick F. (2000). Interactions between adenovirus proteins and the p53 pathway: the development of ONYX-015. Semin Cancer Biol 10: 453-459.
26. 1/S arrest in E1A+c-Haras-transformed cells by Bcl-2 overexpression. Cell Cycle 11: 1427-1432.
27. Oriel JD. (1983). Role of genital mycoplasmas in nongonococcal urethritis and prostatitis. Sex Transm Dis 10: 263-270.
28. Poyurovsky MV, Prives C. (2006). Unleashing the power of p53: lessons from mice and men. Genes Dev 20: 125-131.
29. Prozorovskiy SV, Rakovskaya IV, Vulfovich YuV. (1995). Medical Mycoplasmology. Medicine Publishers: Moscow, Russia, pp 187-188 (in Russian).
30. Razin S, Yogev D, Naot Y. (1998). Molecular biology and pathogenicity of mycoplasmas. Microbiol Mol Biol Rev 62: 1094-1156.
31. Rottem S. (2003). Interaction of mycoplasmas with host cells. Physiol Rev 83: 417-432.
32. Sablina AA, Agapova LS, Chumakov PM, Kopnin BP. (1999). p53 does not control the spindle assembly cell cycle checkpoint but mediates G1 arrest in response to disruption of microtubule system. Cell Biol Int 23: 323-334.
33. Serrano M, Lin AW, McCurrach ME, Beach D, Lowe SW. (1997). Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 88: 593-602.
34. Takeda K, Takeuchi O, Akira S. (2002). Recognition of lipopeptides by Toll-like receptors. J Endotoxin Res 8: 459-463.
35. Tsai S, Wear DJ, Shih JW, Lo SC. (1995). Mycoplasmas and oncogenesis: persistent infection and multistage malignant transformation. Proc Natl Acad Sci USA 22: 10197-10201.
36. Yaswen P, Campisi J. (2007). Oncogene-induced senescence pathways weave an intricate tapestry. Cell 128: 233-234.
37. Zhang B, Shih JW, Wear DJ, Tsai S, Lo SC. (1997). High-level expression of H-ras and c-myc oncogenes in mycoplasma-mediated malignant cell transformation. Proc Soc Exp Biol Med 214: 359-366.